Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components

v3.23.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Components

NOTE 6 — BALANCE SHEET COMPONENTS

Accrued liabilities consisted of the following (in thousands):

 

 

March 31,

2023

 

 

December 31,

2022

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,066

 

 

$

855

 

Clinical trial related costs

 

 

2,023

 

 

 

1,327

 

Non-clinical research and manufacturing operations

 

 

1,182

 

 

 

1,779

 

Payroll related

 

 

1,243

 

 

 

4,828

 

Other accrued expenses

 

 

28

 

 

 

34

 

Total Accrued liabilities

 

$

5,542

 

 

$

8,823